Download PDF
Aktuelle Rheumatologie 2024; 49(02): 85-91
DOI: 10.1055/a-2195-1417
Übersichtsarbeit

Herpes Zoster bei entzündlich-rheumatischen Erkrankungen

Herpes zoster in inflammatory rheumatic diseases
Ruth Charlotte Dartsch
1   Medizinische Klinik D, Sektion für Rheumatologie und klinische Immunologie, Universitätsklinikum Münster, Münster, Germany
,
Nadine Al-Azem
1   Medizinische Klinik D, Sektion für Rheumatologie und klinische Immunologie, Universitätsklinikum Münster, Münster, Germany
,
Rebecca Hasseli
1   Medizinische Klinik D, Sektion für Rheumatologie und klinische Immunologie, Universitätsklinikum Münster, Münster, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Der Herpes Zoster ist eine häufige Viruserkrankung, die meist nach einer jahrzehntelangen Latenz durch eine Reaktivierung einer Varizella-Zoster-Primärinfektion auftritt. Besonders betroffen sind ältere Personen sowie solche mit geschwächtem Immunsystem. Während der akuten Phase zeigen sich dermatombezogene Schmerzen sowie ein papulovesikuläres Exanthem. Die am häufigsten auftretende Komplikation ist die sehr schmerzhafte Post-Zoster-Neuralgie, die über Monate bis zu Jahren anhalten kann. Zur Prävention steht ein Totimpfstoff zur Verfügung, der von der Ständigen Impfkommission (STIKO) als Indikationsimpfung für Personen mit einem entsprechenden Risikoprofil ab dem 50. Lebensjahr sowie als Standardimpfung ab dem 60. Lebensjahr empfohlen wird.

Abstract

Herpes zoster is a viral disease that commonly occurs after a prolonged period of latency due to reactivation of an initial varicella zoster infection. The disease mainly affects older adults and those with impaired immune systems. In the acute phase, individuals experience dermatome-linked pain and papulovesicular rash. The primary complication is excruciating postherpetic neuralgia, which can last several months to years. For precautionary purposes, an inactivated vaccine is available. This vaccine is recommended by the German Standing Committee on Vaccination (STIKO) for individuals with an increased risk profile starting at 50 years of age and as a routine vaccination for individuals aged 60 and older.

Schlüsselwörter

Herpes Zoster - Post-Zoster-Neuralgie - Immunmodulation - Autoimmunerkrankung - Entzündung

Key words

herpes zoster - postherpetic neuralgia - immunomodulation - autoimmune disease - inflammation


Publication History

Article published online:
06 February 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology 2013; 81: 928-930
    CrossrefPubMedSearch in Google Scholar
  • 2 Cohen JI. Herpes Zoster. N Engl J Med 2013; 369: 255-263
    CrossrefPubMedSearch in Google Scholar
  • 3 Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4: e004833-e004833
    CrossrefPubMedSearch in Google Scholar
  • 4 Gross GE, Eisert L, Doerr HW. et al. S2k-Leitlinie zur Diagnostik und Therapie des Zoster und der Postzosterneuralgie. JDDG J Dtsch Dermatol Ges 2020; 18: 55-79
    CrossrefPubMedSearch in Google Scholar
  • 5 Schmader K. Herpes Zoster. Ann Intern Med 2018; 169: ITC17
    CrossrefPubMedSearch in Google Scholar
  • 6 Sundriyal D, Kapoor R, Kumar N. et al Multidermatomal herpes zoster. Case Rep 2014; 2014 bcr2014205024–bcr2014205024
    CrossrefPubMedSearch in Google Scholar
  • 7 Forbes HJ, Thomas SL, Smeeth L. et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 2016; 157: 30-54
    CrossrefPubMedSearch in Google Scholar
  • 8 Oster G, Harding G, Dukes E. et al. Pain, Medication Use, and Health-Related Quality of Life in Older Persons With Postherpetic Neuralgia: Results From a Population-Based Survey. J Pain 2005; 6: 356-363
    CrossrefPubMedSearch in Google Scholar
  • 9 Johnson RW, Bouhassira D, Kassianos G. et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010; 8: 37
    CrossrefPubMedSearch in Google Scholar
  • 10 Niederer RL, Meyer JJ, Liu K. et al. Herpes Zoster Ophthalmicus Clinical Presentation and Risk Factors for Loss of Vision. Am J Ophthalmol 2021; 226: 83-89
    CrossrefPubMedSearch in Google Scholar
  • 11 Schoenberger SD, Kim SJ, Thorne JE. et al. Diagnosis and Treatment of Acute Retinal Necrosis. Ophthalmology 2017; 124: 382-392
    CrossrefPubMedSearch in Google Scholar
  • 12 Monsanto R, Bittencourt A, Bobato Neto N. et al. Treatment and Prognosis of Facial Palsy on Ramsay Hunt Syndrome: Results Based on a Review of the Literature. Int Arch Otorhinolaryngol 2016; 20: 394-400
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Shim HJ, Jung H, Park DC. et al. Ramsay Hunt syndrome with multicranial nerve involvement. Acta Otolaryngol (Stockh) 2011; 131: 210-215
    CrossrefPubMedSearch in Google Scholar
  • 14 Yanni EA, Ferreira G, Guennec M. et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012. BMJ Open 2018; 8: e020528
    CrossrefPubMedSearch in Google Scholar
  • 15 Gupta G, Lautenbach E, Lewis JD. Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2006; 4: 1483-1490
    CrossrefPubMedSearch in Google Scholar
  • 16 Yun H, Yang S, Chen L. et al. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheumatol 2016; 68: 2328-2337
    CrossrefPubMedSearch in Google Scholar
  • 17 Forbes HJ, Bhaskaran K, Thomas SL. et al. Quantification of risk factors for herpes zoster: population based case-control study. BMJ 2014; 348: g2911
    CrossrefPubMedSearch in Google Scholar
  • 18 Ehrenstein B. Diagnostik, Therapie und Prophylaxe des Herpes zoster. Z Für Rheumatol 2020; 79: 1009-1017
    CrossrefPubMedSearch in Google Scholar
  • 19 Galloway J, Raine T, Rivett L. et al. Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clin Exp Rheumatol 2021;
    CrossrefPubMedSearch in Google Scholar
  • 20 Marra F, Lo E, Kalashnikov V. et al. Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infect Dis 2016; 3: ofw205
    CrossrefPubMedSearch in Google Scholar
  • 21 Redeker I, Albrecht K, Kekow J. et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis 2022; 81: 41-47
    CrossrefPubMedSearch in Google Scholar
  • 22 Dworkin RH, Barbano RL, Tyring SK. et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009; 142: 209-217
    CrossrefPubMedSearch in Google Scholar
  • 23 Rodríguez MJ, Díaz S, Vera-Llonch M. et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007; 23: 2585-2596
    CrossrefPubMedSearch in Google Scholar
  • 24 Rowbotham M, Harden N, Stacey B. et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-1842
    CrossrefPubMedSearch in Google Scholar
  • 25 Wang S-L, Wang H, Nie H-Y. et al. The efficacy of pregabalin for acute pain control in herpetic neuralgia patients: A meta-analysis. Medicine (Baltimore) 2017; 96: e9167
    CrossrefPubMedSearch in Google Scholar
  • 26 Wiffen PJ, Derry S, Bell RF. et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017; 6: CD007938
    CrossrefPubMedSearch in Google Scholar
  • 27 Watson CP. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain 2000; 16: S49-55
    CrossrefPubMedSearch in Google Scholar
  • 28 Kennedy WR, Vanhove GF, Lu S-P. et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 2010; 11: 579-587
    CrossrefPubMedSearch in Google Scholar
  • 29 Derry S, Wiffen PJ, Moore RA. et al. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev 2014; 2014: CD010958
    CrossrefPubMedSearch in Google Scholar
  • 30 Khaliq W, Alam S, Puri NK. Topical lidocaine for the treatment of postherpetic neuralgia. In: The Cochrane Collaboration, Hrsg. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007: CD004846 pub2
    Search in Google Scholar
  • 31 RKI – RKI-Ratgeber – Windpocken (Varizellen), Gürtelrose (Herpes zoster). Im Internet https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Varizellen.html#doc2374554bodyText14 Stand: 09.10.2023
    PubMed
  • 32 Cunningham AL, Lal H, Kovac M. et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016; 375: 1019-1032
    CrossrefPubMedSearch in Google Scholar
  • 33 Lal H, Cunningham AL, Godeaux O. et al. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. N Engl J Med 2015; 372: 2087-2096
    CrossrefPubMedSearch in Google Scholar
  • 34 Dagnew AF, Ilhan O, Lee W-S. et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 2019; 19: 988-1000
    CrossrefPubMedSearch in Google Scholar
  • 35 Vink P, Ramon Torrell JM, Sanchez Fructuoso A. et al. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. Clin Infect Dis 2020; 70: 181-190
    CrossrefPubMedSearch in Google Scholar
  • 36 Vink P, Delgado Mingorance I, Maximiano Alonso C. et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. Cancer 2019; 125: 1301-1312
    CrossrefPubMedSearch in Google Scholar
  • 37 Übersicht über Shingrix und warum es in der EU zugelassen ist https://www.ema.europa.eu/en/documents/overview/shingrix-epar-medicine-overview_de.pdf (Stand 2023-10-17)
    PubMed
  • 38 Robert-Koch-Institute. Wissenschaftliche Begründung für die Entscheidung, die Herpeszoster-Lebendimpfung nicht als Standardimpfung zu empfehlen (https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2017/Ausgaben/36_17.pdf?__blob=publicationFile, abgerufen am 2023-10-17)
    PubMed
  • 39 Varan Ö, Babaoğlu H, Göker B. Associations between Depressive Disorders and Inflammatory Rheumatic Diseases. Curr Top Med Chem 2018; 18: 1395–1401. DOI: 10.2174/1568026618666180516100805. PMID: 29766809
    PubMed